anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This product is for intravenous use only.

Adult Dosage: The recommended adult dose of ARRANON is 1500 mg/m2 administered intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days. Administer ARRANON undiluted.

Pediatric Dosage: The recommended pediatric dose of ARRANON is 650 mg/m2 administered intravenously over 1 hour daily for 5 consecutive days repeated every 21 days. Administer ARRANON undiluted.

The recommended duration of treatment for adult and pediatric patients has not been clearly established. In clinical trials, treatment was generally continued until there was evidence of disease progression, the patient experienced unacceptable toxicity, the patient became a candidate for hematopoietic stem cell transplantation (HSCT), or the patient no longer continued to benefit from treatment.
Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel \& Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel \& Sakallı, 2016).
In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
Chronic idiopathic patellofemoral pain, a potential precursor to osteoarthritis, is one of the most common problems of the knee. It is characterized by anterior knee pain that is aggravated by deep knee flexion, prolonged sitting, and repetitive flexion/extension. The most widely accepted theory in regards to the source of this pain is that a force imbalance around the knee leads to static patellofemoral malalignment and dynamic patellofemoral maltracking. In turn, this malalignment and maltracking leads to elevated joint contact stresses, which ultimately leads to patellofemoral pain. Current understanding of patellofemoral maltracking is typically focused on static 2D alignment (lateral tilt and displacement). Yet, patellofemoral pain is most often exacerbated during dynamic events and the patella has complete six degrees of freedom in its movement. More recent studies have been able to quantify patellofemoral kinematics during volitional dynamic tasks and demonstrate that the maltracking problem is more complex than originally postulated. Specifically, in patients with patellofemoral pain, altered kinematics are not limited to excessive patellar lateral translation and tilt, but include excessive patellar superior translation along with excessive flexion and valgus rotations. Flexion and valgus are sagittal and coronal plane rotations that cause the superior pole of the patella to shift anteriorly and medially, respectively. Recent work has shown that altered force balance around the knee can indeed lead to maltracking. However, the question remains whether correcting an existing force imbalance around the knee can normalize patellar kinematics and/or reduce pain. The purpose of this study is to determine how temporary iatrogenic loss of force in the vastus lateralis muscle alters the aberrant patellar kinematics in subjects with chronic idiopathic patellofemoral pain.
Implementations described and claimed herein provide systems, apparatuses, and methods for providing cardiovascular exercise by simulating an exercise experience, such as a jump rope experience. In one implementation, a pair of exercise simulators is provided. Each of the exercise simulators includes a spin assembly rotationally mounted to a handle along an axis line. The spin assembly is configured to rotate about the axis line. At least one weight is housed in the spin assembly, and a light source is configured to rotate about the axis line with the spin assembly. The light source is configured to emit light to provide a visual representation of the motion of the spin assembly.
Lung cancer is a serious health and life issue, with the fastest-growing incidence and fatality rates worldwide. It is now clear that inflammation is a key factor involved in all aspects of carcinogenesis, notably lung cancer development. Genetic changes, including polymorphisms in inflammatory genes, are supposed to be a significant cause of increased lung cancer risk. The main idea of this research was to disclose the linkage between both IL-6 rs1800795 and IL-1β rs16944 variants and susceptibility to non-small-cell lung cancer (NSCLC) in Egyptians. This case-control design was composed of 127 cases and 138 controls, which were genotyped using the ARMS-PCR technique. To examine the NSCLC susceptibility under various genetic models, the odds ratio (OR) and 95% confidence intervals (CIs) were determined by logistic regression. Rs1800795 of the IL-6 gene was linked to higher odds of NSCLC under the allele model (adjusted, OR 2.28; 95% CI 1.2-4.33; p = 0.011). In the genetic models, IL-6 rs1800795 elevated the odds of NSCLC, while IL-1β rs16944 decreased the odds of NSCLC. Stratification analysis showed that IL-6 rs1800795 greatly increased the NSCLC risk in females and adenocarcinoma subtypes, whereas IL-1β rs16944 largely decreased the NSCLC risk for males, patients aged < 55, and nonsmokers. Regarding clinical data, the IL-6 variant was remarkably correlated with tumor size. This work primarily established that IL-6 and IL-1β variants have a great impact on NSCLC development in the Egyptian population; thus, it may be a supportive guide for earlier NSCLC prevention.
The invention provides a lyophilized tablet prepared from a captopril composition and a preparation method thereof and belongs to the technical of medicines and medicine production. The lyophilized tablet is prepared from captopril, starch and sucrose, wherein the starch and the sucrose serve as adjuvants. By heating the common corn starch, the binding and disintegrating effects of the starch in the lyophilized tablet can be improved, and the formability of the lyophilized tablet can be improved. The adjuvants for preparing the lyophilized tablet only comprise the starch and the sucrose. The lyophilized tablet is prepared by decreasing temperature twice and increasing temperature twice, and the twice temperature decrease and twice temperature increase can ensure that the lyophilized tablet can be well formed, the dissolution rate of the lyophilized tablet can be increased and the bioavailability of the lyophilized tablet can be improved. The lyophilized tablet overcomes the defects of the ordinary tablet prepared from captopril, is prepared by adopting a few kinds of and a small amount of adjuvants compared with the tablet prepared from captopril, has high dissolution rate and high bioavailability, has a good clinical treatment effect and can be used for clinical treatment safely.
The present invention discloses active rubusoside and a production method thereof. The active rubusoside is made from purely natural sweet stevia leaves as raw materials through the processes of picking, scalding, cooling, dewatering, drying, disintegrating, crushing, etc. As required, a handling process of segment cutting can be increased after the process of dewatering, the processes of selecting and impurity removing can be increased after the process of drying, and then the processes of molding and packaging are executed for preparing the active rubusoside. The prepared active rubusoside has various health care functions of the sweet stevia leaves and is a sweetening agent with the advantages of low calorific power, high sweetness and mellow and normal taste. The active rubusoside of the present invention is a purely natural green product with the advantages of no additives, no harmful side effects, good water solubility, no fishy smell of grass and peculiar smell during eating, no peculiar leaf dreg sense, bright green colour and very good taste, and not only can be widely used for beverages, coffee, milk and cooking but also can be used for the food processing of candies, pastries, cakes, etc. The active rubusoside is an ideal food product instead of sugar for patients of adiposis, diabetes and cardio-cerebrovascular disease and people who are not suitable for eating sucrose.
Problem: To provide a brown/beige adipocyte activating agent and a brown/beige adipocyte activating food each containing D-allulose as an active ingredient. Solution: A brown/beige adipocyte activating agent containing D-allulose as an active ingredient. A brown/beige adipocyte activating agent containing at least D-allulose and having an UCP-1 expression promoting activity. A brown/beige adipocyte activating agent which can enhance the expression of UCP-1 to activate a brown/beige adipocyte. An energy consumption promoting agent containing D-allulose as an active ingredient. An energy consumption promoting agent which can activate a brown/beige adipocyte to promote the consumption of an energy. A UCP-1 expression enhancing agent containing D-allulose as an active ingredient. A composition or a food composition, which contains any one of the aforementioned agents.
The invention provides a preparation method of a pharmaceutical composition containing root of red-rooted salvia. The method comprises the following steps: with water or ethanol solution as an extracting solvent under control of pressure, heating, refluxing and extracting the root of red-rooted salvia; preferably, firstly heating, refluxing and extracting the root of red-rooted salvia by the ethanol solution under control of pressure, and then heating, refluxing and extracting dregs of the root of red-rooted salvia by water. The pharmaceutical composition provided by the invention also can contain pseudo-ginseng, borneol and the like. The preparation method comprises the following steps: independently or simultaneously putting the root of red-rooted salvia and the pseudo-ginseng into an extracting system under control of pressure; and with the water or ethanol solution as the extracting solvent, heating, refluxing and extracting. The invention also provides the pharmaceutical composition prepared by the preparation method. Compared with atmospheric reflux extraction, the preparation method disclosed by the invention has the advantages that the content of effective components of the root of red-rooted salvia can be significantly increased; the damage to the components of the root of red-rooted salvia caused by high temperature and long heating time is reduced; meanwhile, the extracting time and solvent consumption can be shortened and reduced.
A mHealth app (iCKD APP) was designed to assist CKD patients to monitor their home bio-information data. Patients will be randomly assigned into the iCKD APP group(intervention) and traditional care group (control). Participants will be randomized into an 1:1 manner (intervention : control). Random assignment occurred after the consent and initial enrollment interview. Individuals randomized to the iCKD APP will provide with the equipment after randomization. Participants will follow for at least 6 months before the exit interview.
PURPOSE:To perform the necessary medicine compounding jobs even in case the prescribing contents are not concrete by providing prescription data accepting means, a reference data accepting means and a prescription information producing means. CONSTITUTION:When an IC card containing the prescription data is applied, an accepting member 1 reads the prescription data and accepts it. A converting member 6 converts the prescription data into the prescription information on the medicine names, the dose, etc., and also records them on a memory medium 4. While an accepting member 2 reads the reference data for acceptance when a reserved prescription card, etc., are applied. A producing member 3 retrieves the medium 4 in response to the reference data and based on the identification code of the preceding prescription and reads the prescription data out of a preceding prescription master for production of the prescription information. In the case of the reserved prescription, a memory medium 5 is retrieved based on the reserved prescription number and the prescription information is produced from the reserved prescription master. The prescription information delivered from both means 6 and 3 are arranged in the prescribed order by an arrangement member 7 to be delivered to a display device, a memory, a printer, etc.
The invention includes a method of dehydration of a sugar using a dehydration catalyst and a co-catalyst within a reactor. A sugar is introduced and H 2  is flowed through the reactor at a pressure of less than or equal to about 300 psig to convert at least some of the sugar into an anhydrosugar product. The invention includes a process for producing isosorbide. A starting material comprising sorbitol is flowed into a reactor. H 2  is counter flowed through the reactor. The starting material is exposed to a catalyst in the presence of a co-catalyst which comprises at least one metal. The exposing is conducted at a hydrogen pressure of less than or equal to 300 psig within the reactor and the hydrogen removes at least some of any water present during the exposing and inhibits formation of colored byproducts.
Hepatocellular carcinoma(HCC) ranks the 6th most common cancer and is the 2nd leading cause of cancer-related death globally. Surgical resection remains the most efficient therapy in early stage. Though an anatomical resection of tumor lead to an up to 70% 5-year overall survival, the existence of micro vascular invasion(MVI) caused early recurrence. Stereotactic body radiation therapy (SBRT) has been proved to be efficient in treating vascular tumor thrombosis. The investigators tried to implement this technique in adjuvant setting for HCC after surgery with MVI. Participants with early stage HCC whose tumor locates closely to the main intrahepatic vascular will be regarded as potentially-not-enough-surgical-margin candidates. Surgical resection will be carried out as scheduled and an additional silver clip will be put into the margin. Postoperative pathological examination will detect micro vascular invasion or daughter nodule. MVI-positive candidates will be eligible for enrollment. Eligible participants will be randomized to two groups, SBRT group and surgery-alone(SA) group with 1-to-1 ratio. Participants in SBRT group will receive a 35Gy limited resection margin parenchyma SBRT after surgery, while participants in SA group just get surgery. Radiation related adverse events (AE) or reaction will be recorded and intervened necessarily. All participants will be followed up by investigators every three months. DFS, OS, and AEs are end points in this study.
Group 1 consisted of COPD patients not receiving any treatment ( inhaled and/or systemic steroids, long-acting inhaled beta-2 agonists alone, theophylline and combined long-acting beta-2 agonists and long-acting anticholinergic ). These patients are early stage COPD patients.
Provided is a data processing method for determining rotation by a marker device of a medical tracking system about its mount. The data processing method includes acquiring a first marker device position dataset which represents a position of the marker device before a movement of the marker device. A second marker device position dataset is acquired which represents the position of the marker device after a movement of the marker device. A marker device displacement dataset is calculated, which represents the displacement of the marker device, from the first and second marker device position datasets. At least one axis of rotation of the marker device displacement dataset is calculated. A determination is made whether or not the marker device is rotated about its mount from the position of the at least one axis of rotation relative to the marker device.
Enrolled participants who met inclusion criteria (full-time clinical nurses working for at least five days during a specified 10-day period) were randomized in 1:1 ratio to the coloring or control groups. A third party did the allocation sequence and concealment. After giving informed consent, participants completed the baseline questionnaire and the coloring group watched an instructional video on mindful coloring. The coloring group were asked to color for any length of time on at least five working days during a 10-day period (period A) while the control group were asked to do it on a subsequent 10-day (period B). The post-intervention questionnaire was completed by both groups at the end of period A. The study was completed after period B.
The present invention provides a medicine, which cures a refractory canker sore, Behcet disease and a sjogren syndrome and a preparation method of the medicine. The symptoms are common clinical diseases at present. The current domestic and overseas treatments can only relieve the external symptoms; a curative effect is not ideal and the diseases are easy to recrudesce. The component of the present invention includes Chinese traditional medicines, and the weight portion ratio of the Chinese traditional medicines is 10 portions dried rehmannia root, 10 portions dyers woad leaf, 8 portions danshen root, 5 portions milk vetch root, 6 portions heterophylly falsesatarwort root, 5 portions aweto, 6 portions tuber of dwarf lilyturf, 3 portions Manchurian wildginger, 8 portions cistanche, 8 portions red peony root, 6 portions lonicera, 10 portions green bristle grass, 6 portions herb of wild mint, 6 portions Chinese thorowax root, 5 portions ginseng and 10 portions largehead atractylode. The component of the present invention also includes 10 portions dangshen, 9 portions scutellaria, 9 portions moutan bark, 10 portions lophatherum, 10 portions talc, 6 portions coptis chinensis, 6 portions fresh ginger and 10 portions glycyrrhizae. A leechdom of the present invention cures the refractory canker sore, the Behcet disease and the sjogren syndrome.
Hemopoietic depression is the most common toxicity with dacarbazine for injection and involves primarily the leukocytes and platelets, although anemia may sometimes occur. Leukopenia and thrombocytopenia may be severe enough to cause death. The possible bone marrow depression requires careful monitoring of white blood cells, red blood cells, and platelet levels. Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with dacarbazine for injection.

Hepatic toxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, has been reported. The incidence of such reactions has been low; approximately 0.01% of patients treated. This toxicity has been observed mostly when dacarbazine for injection has been administered concomitantly with other anti-neoplastic drugs; however, it has also been reported in some patients treated with dacarbazine for injection alone.

Anaphylaxis can occur following the administration of dacarbazine for injection.
INTRODUCTION: Unplanned transfers from the General Ward to Critical Care Units occur due to a deterioration in the patient's clinical status. They are of great interest because of their negative impact, associated with longer hospital stays and higher mortality.
OBJECTIVES: To report the frequency at which these transfers occur, characteristics of these patients and causes of the transfer. Identify shortcomings in the care process that may allow improvement strategies.
METHODOLOGY: cross-sectional study. Cases were considered those who, during the first 24 hours of hospitalization in the General Ward, required transfer to the ICU between January - December 2022 in a high-complexity hospital in Buenos Aires. Results: Of 8317 admissions, 124 were transferred to the ICU, with a rate of 14 per 1000 and an average of 70 years. The most frequent comorbidities were high blood pressure, heart failure, cancer and overweight-obesity. The main causes of hospitalization were respiratory and gastrointestinal symptoms. 67% had non-alarming results in the NEWS score prior to transfer to the ICU. The most frequent causes were respiratory failure, hemodynamic instability and requirement for monitoring. Average hospital stay was 10 days and in-hospital mortality was 26%.
CONCLUSIONS: Respiratory decompensation in elderly male patients was the most common cause of transfer to a Closed Unit. One of the shortcomings of the care process seems to be the NEWS score, where in 67% of cases it did not warn about the high requirement of patient monitoring.
OSA is associated with increased risk of cardiovascular and cerebrovascular disease compared to the general population. The mechanism for the increased stroke risk in OSA is unknown. However, the constellation of adverse pathophysiological consequences, including intermittent hypoxia and carbon-dioxide retention as a result of OSA may be detrimental to CVR and predispose the brain to ischemia. Previous studies in OSA subjects have measured CVR only using TCD. Therefore, our study will examine CVR by two methods (TCD and BOLD-MRI) with reliable and reproducible hypercapnia and independent control of oxygen saturation (RespiractTM). Patterns seen on CVR may eventually allow the identification of OSA patients who will be at greatest risk for stroke and will therefore, require aggressive risk reduction and/or treatment irrespective of symptoms.
Doxorubicin (DOX) is an anthracycline antibiotic used as an antitumor treatment. However, its clinical application is limited due to severe side effects such as cardiotoxicity. In recent years, numerous studies have demonstrated that cellular aging has become a therapeutic target for DOX-induced cardiomyopathy. However, the underlying mechanism and specific molecular targets of DOX-induced cardiomyocyte aging remain unclear. Poly (ADP-ribose) polymerase (PARP) is a family of protein post-translational modification enzymes in eukaryotic cells, including 18 members. PARP-1, the most well-studied member of this family, has become a potential molecular target for the prevention and treatment of various cardiovascular diseases, such as DOX cardiomyopathy and heart failure. PARP-1 and PARP-2 share 69% homology in the catalytic regions. However, they do not entirely overlap in function. The role of PARP-2 in cardiovascular diseases, especially in DOX-induced cardiomyocyte aging, is less studied. In this study, we found for the first time that down-regulation of PARP-2 can inhibit DOX-induced cellular aging in cardiomyocytes. On the contrary, overexpression of PARP-2 can aggravate DOX-induced cardiomyocyte aging and injury. Further research showed that PARP-2 inhibited the expression and activity of SIRT1, which in turn was involved in the development of DOX-induced cardiomyocyte aging and injury. Our findings provide a preliminary experimental basis for establishing PARP-2 as a new target for preventing and treating DOX cardiomyopathy and related drug development.
This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.